Chronic Intestinal Pathologies Analytical Cohort at TouLouse

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-29

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the general population, the percentage of people with at least one digestive disease is 16.7%. Among these digestive diseases, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and patients who should benefit from digestive examinations as part of a screening oriented either by the patient's family history or following the performance of an immunological screening test ( FIT) in the stool will be studied. The aim of this project is to build a biological collection with associated clinical data for research projects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease

NCT05733845

Crohn's Disease Ulcerative Colitis

RECRUITING NA

Characterization of the Intestinal Microbiota in Patients With Inflammatory Bowel Disease and/or Spondyloarthritis and Study of the Impact of an Anti-TNF Alpha Therapy

NCT03359642

Spondyloarthritis Crohn Disease Ulcerative Colitis

COMPLETED NA

NKT Role in the Regulation of the Inflammatory Bowel Disease

NCT02884557

Inflammatory Bowel Diseases Primary Sclerosing Cholangitis

COMPLETED NA

A Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted Therapies

NCT05456893

Ulcerative Colitis Inflammatory Bowel Diseases

RECRUITING

Characterization of Phenotype and Genotype of Early Onset Enteropathies

NCT02614911

Inflammatory Bowel Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the general population, the percentage of people with at least one digestive disease is 16.7%. Among these digestive diseases, two of them namely inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) will be more particularly studied. This interest is based on the increasing frequency of these two pathologies, their chronicities but above all the limited physiopathological data available. In addition, it seems interesting to study a third population, namely patients who should benefit from digestive examinations as part of a screening oriented either by the patient's family history or following the performance of an immunological screening test ( FIT) in the stool. The study of this population is part of an improvement in knowledge on the carcinogenesis of colorectal cancer.

To study these populations, blood, serum, plasma and tissues from colonous biopsies or surgical samples will be collected.

This cohort will make it possible to study, among other things, the pathophysiology of chronic diseases of the small intestine and the colon (IBD, IBS, screening) in order to improve their management through the development of new biomarkers and therapeutic targets.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Diseases Colon Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient screened or followed-up for IBS or IBD or colorectal cancer

Blood and colon biopsy sampling

blood and intestinal biopsy sampling

Intervention Type BIOLOGICAL

24 mL of blood and 10 intestinal biopsies will be sampled

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood and intestinal biopsy sampling

24 mL of blood and 10 intestinal biopsies will be sampled

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient requiring endoscopic explorations for screening or follow-up in the context of a suspected IBS or IBD or colorectal cancer Or
* Patient with IBD requiring surgical management
* Patient over 18 years old
* Patient able to read and understand the information leaflet
* Patients who have given their consent to participate in the study
* Patients affiliated to a social security system (including AME)

Exclusion Criteria

* Patients who have received antibiotic treatments in the 10 days preceding endoscopic exploration
* Pregnant or breastfeeding patients
* Patients under 18 years old
* Patients under guardianship or curatorship
* Patients unable to sign a free and informed consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No